Bioventus (BVS) Operating Expenses (2020 - 2026)

Bioventus (BVS) has reported Operating Expenses for 7 consecutive years, with $85.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses rose 3.91% year-over-year to $85.5 million; the trailing twelve-month figure through Jun 2026 stood at $334.1 million (changed 0.04% YoY), and the FY2025 full-year result was $336.4 million, down 8.64% from the prior year.
• Operating Expenses rose to $85.5 million in Q2 2026 per BVS's latest filing, from $81.2 million in the prior quarter.
• Across five years, Operating Expenses topped out at $100.9 million in Q2 2024 and bottomed at $72.8 million in Q3 2023.
• Historically, Operating Expenses has averaged $85.1 million across 5 years, with a median of $84.5 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses soared 162.76% in 2022, then decreased 18.69% in 2023.
• Over 5 years, Operating Expenses stood at $88.0 million in 2022, then retreated by 7.33% to $81.5 million in 2023, then rose by 10.48% to $90.1 million in 2024, then retreated by 4.8% to $85.8 million in 2025, then decreased by 0.31% to $85.5 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $85.5 million, $81.2 million, and $85.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.